Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lore Santoro

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Pharmaceutics|April 28, 2023
<sup>225</sup>Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to ClinicLéa Rubira, Emmanuel Deshayes, Lore Santoro, et al.
Current Radiopharmaceuticals|February 29, 2024
"One Method to Label Them All": A Single Fully Automated Protocol for GMP-Compliant <sup>68</sup>Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617Juliette Fouillet, Charlotte Donzé, Emmanuel Deshayes, et al.
BMC Cancer|December 22, 2022
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH)Emmanuel Deshayes, Eric Assenat, Laetitia Meignant, et al.
European Journal of Drug Metabolism and Pharmacokinetics|May 15, 2023
Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera<sup>®</sup>) CaseAnissa Barakat, Lore Santoro, Myrtille Vivien, et al.
Hellenic Journal of Nuclear Medicine|August 5, 2021
Whole body planar and 3D quantitative imaging after <sup>177</sup>Lu-DOTATATE on CZT SPECT/CT device with MEHRS collimator. First reportEmmanuel Deshayes, Cyril Fersing, Kévin Hébert, et al.
Healthcare (Basel, Switzerland)|November 11, 2022
Development and Implementation of a Professional Practices Evaluation during Radiopharmaceuticals AdministrationCharlotte Donzé, Léa Rubira, Lore Santoro, et al.
European Journal of Hospital Pharmacy : Science and Practice|September 13, 2022
<sup>177</sup>Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methodsCharlotte Donzé, Léa Rubira, Lore Santoro, et al.
EJNMMI Research|January 4, 2021
Clinical implementation of PLANET® Dose for dosimetric assessment after [<sup>177</sup>Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0Lore Santoro, L Pitalot, D Trauchessec, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 10, 2025
Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward!Emmanuel Deshayes, Ioannis Karfis, Lore Santoro, et al.
EJNMMI Research|December 1, 2018
Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [<sup>177</sup>Lu-[DOTA0, Tyr3]-octreotateLore Santoro, Erick Mora-Ramirez, Dorian Trauchessec, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Pharmaceutics|April 28, 2023
<sup>225</sup>Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to ClinicLéa Rubira, Emmanuel Deshayes, Lore Santoro, et al.
Current Radiopharmaceuticals|February 29, 2024
"One Method to Label Them All": A Single Fully Automated Protocol for GMP-Compliant <sup>68</sup>Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617Juliette Fouillet, Charlotte Donzé, Emmanuel Deshayes, et al.
BMC Cancer|December 22, 2022
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH)Emmanuel Deshayes, Eric Assenat, Laetitia Meignant, et al.
European Journal of Drug Metabolism and Pharmacokinetics|May 15, 2023
Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera<sup>®</sup>) CaseAnissa Barakat, Lore Santoro, Myrtille Vivien, et al.
Hellenic Journal of Nuclear Medicine|August 5, 2021
Whole body planar and 3D quantitative imaging after <sup>177</sup>Lu-DOTATATE on CZT SPECT/CT device with MEHRS collimator. First reportEmmanuel Deshayes, Cyril Fersing, Kévin Hébert, et al.
Healthcare (Basel, Switzerland)|November 11, 2022
Development and Implementation of a Professional Practices Evaluation during Radiopharmaceuticals AdministrationCharlotte Donzé, Léa Rubira, Lore Santoro, et al.
European Journal of Hospital Pharmacy : Science and Practice|September 13, 2022
<sup>177</sup>Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methodsCharlotte Donzé, Léa Rubira, Lore Santoro, et al.
EJNMMI Research|January 4, 2021
Clinical implementation of PLANET® Dose for dosimetric assessment after [<sup>177</sup>Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0Lore Santoro, L Pitalot, D Trauchessec, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 10, 2025
Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward!Emmanuel Deshayes, Ioannis Karfis, Lore Santoro, et al.
EJNMMI Research|December 1, 2018
Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [<sup>177</sup>Lu-[DOTA0, Tyr3]-octreotateLore Santoro, Erick Mora-Ramirez, Dorian Trauchessec, et al.
Pageof 3